Metraipolis › archive › dc_f8c8fc741dea

Amdiglurax — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Amdiglurax
License (as archived)
CC-BY-SA-4.0
Archived
2026-10-31T09:43:40.143Z
SHA-256 of the archived text
85a90d0bb1c237fed2c18747bd49ec36301309c4cb996aced75f444a0f34df54
Stable URL of this page
https://metraipolis.com/documento/dc_f8c8fc741dea

How to cite

Amdiglurax — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Amdiglurax (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_f8c8fc741dea (Metraipolis archive dc_f8c8fc741dea, sha256 85a90d0bb1c237fed2c18747bd49ec36301309c4cb996aced75f444a0f34df54)
BibTeX
@misc{dcf8c8fc741dea,
  title = {Amdiglurax — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Amdiglurax},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_f8c8fc741dea; sha256 85a90d0bb1c237fed2c18747bd49ec36301309c4cb996aced75f444a0f34df54},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Amdiglurax. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Amdiglurax (INNTooltip International Nonproprietary Name), also known by its former developmental code names ALTO-100 and NSI-189 (short for "NeuralStem Inc. 189"), is a drug described as a hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator which is under development for the treatment of major depressive disorder (MDD), bipolar depression, and post-traumatic stress disorder (PTSD). There has also been interest in amdiglurax for possible treatment of cognitive impairment and neurodegeneration. It is taken orally. Amdiglurax's exact mechanism of action is unknown. However, it has been disclosed to act as a highly potent agonist of the TLX. On the other hand, its developer disclosed amdiglurax to act as a dual agonist and positive allosteric modulator ("ago-PAM") of the metabotropic glutamate mGlu5 receptor and attributed its antidepressant-like effects to this action. The drug is thought to work through indirectly enhancing BDNF signaling and increasing neuroplasticity and neurogenesis in the hippocampus. It dose-dependently increases hippocampal volume at sufficiently high doses in rodents. However, the drug did not significantly affect hippocampal volume at the assessed doses in humans in a clinical study. Amdiglurax is a first-in-class drug and a small molecule. As of July 2024, amdiglurax is in phase 2 clinical trials for MDD, bipolar depression, and PTSD. A phase 3 trial for MDD is being planned. Findings of the effectiveness of amdiglurax in treating MDD in phase 1 and 2 trials have been mixed, although cognitive and memory improvements have been observed. Amdiglurax is under development by Alto Neuroscience and was previously under development by Neuralstem, Inc. It has been sold online as a nootropic and antidepressant.

Tema degli esploratori: scienze della vita e salute (deposito sistematico; ricerca «neuroscience»).
Fonte: Wikipedia in inglese, voce «Amdiglurax» — https://en.wikipedia.org/wiki/Amdiglurax
Wikidata Q15409359: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q15409359
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Amdiglurax?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1379413532, consultata il 2026-10-31T09:31:48.087Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 81dfac083b792ea75c54edc69c730d8579c475db39ca016c04a136c4793fce85